BMS Korea
- Company typePublic
- Founded1989
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
BMS Korea firmographics
Firmographics- Name
- BMS Korea
- Legal name
- Bristol-Myers Squibb Company
- Website
- https://bms.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
BMS Korea industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where BMS Korea is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices7 records
Markets served
BMS Korea business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Pharmaceutical Product Sales: BMS generates revenue through the sale of prescription pharmaceutical medicines. Products are distributed through pharmacies, hospitals, and specialty treatment centers. Revenue comes from both newly launched medicines and established brands across oncology, hematology, immunology, neuroscience, and cardiovascular therapeutic areas.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
BMS Korea product offering
Product offeringCore offering
BMS Korea operates as the Korean subsidiary of Bristol Myers Squibb, developing and commercializing prescription pharmaceutical medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company manufactures and sells a portfolio of approved medicines, autologous CAR T cell therapies, and supports a pipeline of 50+ investigational compounds targeting 40+ disease areas.
Product overview
BMS Korea (Bristol Myers Squibb Korea) is the Korean subsidiary of a global biopharmaceutical company offering a portfolio of approved prescription medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company's product portfolio includes its BMS Medicines Portfolio of approved drugs, CAR T Cell Therapy (with 2 approved therapies and 3+ in clinical trials), and a robust pipeline of 50+ compounds targeting 40+ disease areas. Services include Cancer Care Patient Resources, Disease State Resources (fact sheets for various cancers), Investigational Medicine Access Programs (Pre-Approval Access and Post Study Drug Access), and Competitive Research Grants for independent investigators. Research platforms focus on protein degradation using cryo-EM technology and a comprehensive cancer research approach combining tumor intrinsic and extrinsic mechanisms across multiple therapeutic modalities including immunotherapies, protein degraders, cell therapies, targeted therapies, and antibody-drug conjugates.
Differentiator
Problem solved
Functional benefit
Products and services
- BMS Medicines Portfolio
Quantifiable outcome
- ~14 million patients reached globally with BMS medicines in 2025
- +2 more outcomes
Companies that use BMS Korea
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
BMS Korea technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BMS Korea partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Nektar TherapeuticscoreBMS entered into a strategic Immuno-Oncology collaboration with Nektar Therapeutics for the development of a selective IL-2 receptor agonist. This partnership focuses on harnessing the ability to selectively target IL-2 receptors on T cells to increase immune cells in the tumor microenvironment, potentially expanding benefits to more cancer patients when combined with other mechanisms such as PD-1 inhibitors.
- Ono Pharmaceutical Co., Ltd.coreBMS collaborates with Ono Pharmaceuticals for research and development activities in Japan, Korea, and Taiwan. This partnership enables BMS to expand its presence and conduct clinical research across these Asian markets through Ono's established regional infrastructure and expertise.
- Clinical Trial InvestigatorscoreBMS works with clinical trial investigators and research institutions globally to conduct clinical trials across its pipeline. The company accepts investigator-sponsored research (ISR) proposals in oncology, hematology, cardiovascular, and immunology through its FastTrack Investigator Portal.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
BMS Korea competitors and assessment
Company assessmentDirect peers
- Novartis: Direct competitor in CAR T cell therapy (Kymriah), oncology, hematology, and cardiovascular. Highly comparable modality strategy spanning cell therapy, radioligand therapy, and small molecules.
- AbbVie: Specialty biopharma with deep immunology (Humira/Skyrizi/Rinvoq) and oncology franchises (hematology). Comparable specialty pharma model and post-LoE pipeline replenishment challenge.
- Sanofi: Competitor in immunology, oncology, and rare disease with a similar mix of specialty pharmaceuticals and biologics. Overlapping therapeutic area focus and global commercial model.
- AstraZeneca: Competitor in oncology (checkpoint inhibitors, ADCs), cardiovascular, and respiratory/immunology. Strong direct overlap in immuno-oncology and combination therapy development.
- Merck & Co. Global biopharmaceutical leader with deep oncology (Keytruda checkpoint inhibitor) and vaccines franchises. Directly comparable to BMS across immuno-oncology, hematology, and pipeline-modality strategy.
- Pfizer: Large-cap diversified biopharmaceutical company with overlapping oncology, immunology, and cardiovascular portfolios. Competes head-to-head across therapeutic areas and pipeline modalities.
- Roche: Global biopharma with strong oncology, hematology, and immunology franchises and significant biologics manufacturing capability. Closely comparable to BMS in cancer pipeline depth and specialty pharma mix.
- GSK: Global biopharma competing across oncology, immunology, and cardiovascular. Comparable in oncology pipeline build-out and specialty pharma positioning.
- Eli Lilly: Direct peer across oncology, immunology, and neuroscience, with growing cardiometabolic presence. Comparable in R&D scale and global launch capability.
- Johnson & Johnson: Diversified biopharma with overlapping oncology, immunology, and cardiovascular franchises. Comparable in scale, pipeline breadth, and global commercial reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
BMS Korea social profiles
Digital presenceBMS Korea financial estimates
Financial estimateRevenue estimate
Valuation estimate
BMS Korea leadership team
Management profileNumber of profiles
BMS Korea subsidiaries and ownership
Company hierarchySubsidiaries1 record
BMS Korea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BMS Korea M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BMS Korea
What does BMS Korea do?
BMS Korea operates as the Korean subsidiary of Bristol Myers Squibb, developing and commercializing prescription pharmaceutical medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company manufactures and sells a portfolio of approved medicines, autologous CAR T cell therapies, and supports a pipeline of 50+ investigational compounds targeting 40+ disease areas.
Is BMS Korea a public or private company?
BMS Korea is a public company. It is classified as public and is currently operating.
When was BMS Korea founded?
BMS Korea was founded in 1989. It employs 101 to 250 people.
Where is BMS Korea based?
BMS Korea is headquartered in Seoul, South Korea, in the Asia region.
How does BMS Korea make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are BMS Korea's main competitors?
Direct peers on record are Novartis, AbbVie, Sanofi, AstraZeneca, Merck & Co., Pfizer, Roche, GSK, Eli Lilly and Johnson & Johnson.
Does BMS Korea have an API?
No public API is recorded for BMS Korea.
What industry is BMS Korea in?
BMS Korea's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.